MedTrace Logo

Phase 2 Trial Evaluating the Efficacy and Safety of RBD5044 in Patients With Mixed Dyslipidemia

NCT06797401 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2026-03-12

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if drug RBD5044 works to treat mixed dyslipidemia in adults. It will also learn about the safety of drug RBD5044. The main questions it aims to answer are:

Does drug RBD5044 reduce the triglyceride levels? What medical problems may participants experience when taking drug RBD5044? Researchers will compare drug RBD5044 to a placebo to see if drug RBD5044 works to treat mixed dyslipidemia.

Participants will:

Receive RBD5044 or placebo twice during the trial (Day 1 and Day 84). Visit the clinic 11 times during 12 months (visit every 4-8 weeks) for checkups and tests.

Conditions

  • Dyslipidemias

Interventions

DRUG

RBD5044

RBD5044, active drug.

DRUG

Placebo

Placebo that is identical in appearance and volume to the doses of active IMP.

Sponsors & Collaborators

  • Ribocure Pharmaceuticals AB

    lead INDUSTRY

Principal Investigators

  • Sara Svedlund, MD, PhD · Ribocure Clinic/Ribocure Pharmaceuticals AB

  • David Erlinge, MD, PhD · Lunds Universitetssjukhus

  • Emil Hagström, MD, PhD · Akademiska Sjukhuset Uppsala

  • Åke Olsson, MD, PhD · AkardoMedSite

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-28
Primary Completion
2026-05-31
Completion
2026-09-30

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06797401 on ClinicalTrials.gov